NASDAQ:NVCR - Novocure Stock Price, Forecast & News

Novocure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NVCR stock has increased by 3.9% and is now trading at $70.04. View which stocks have been mosted impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novocure in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novocure.

Novocure is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Novocure.

Novocure Ltd (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, February, 27th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.02 by $0.02. The medical equipment provider earned $99.23 million during the quarter, compared to analysts' expectations of $99.10 million. Novocure had a negative net margin of 2.06% and a negative return on equity of 4.17%. The company's quarterly revenue was up 42.4% compared to the same quarter last year. During the same period last year, the company earned ($0.17) EPS. View Novocure's earnings history.

Novocure issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $351.3-351.3 million, compared to the consensus revenue estimate of $347.69 million.

6 brokerages have issued 12 month target prices for Novocure's shares. Their forecasts range from $79.00 to $97.00. On average, they anticipate Novocure's stock price to reach $87.40 in the next year. This suggests a possible upside of 24.8% from the stock's current price. View analysts' price targets for Novocure.

Headlines about NVCR stock have trended very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novocure earned a coverage optimism score of -3.7 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutNovocure.

Some companies that are related to Novocure include DexCom (DXCM), FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), Insulet (PODD), Hill-Rom (HRC), ABIOMED (ABMD), Penumbra (PEN), Haemonetics (HAE), Globus Medical (GMED), Tandem Diabetes Care (TNDM), ICU Medical (ICUI), Integra Lifesciences (IART), Nevro (NVRO) and NuVasive (NUVA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novocure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), NVIDIA (NVDA) and Roper Technologies (ROP).

Novocure trades on the NASDAQ under the ticker symbol "NVCR."

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVCR stock can currently be purchased for approximately $70.04.

Novocure has a market capitalization of $6.98 billion and generates $351.32 million in revenue each year. The medical equipment provider earns $-7,230,000.00 in net income (profit) each year or ($0.07) on an earnings per share basis.  View additional information about Novocure.

The official website for Novocure is http://www.novocure.com/.

Novocure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 44-0-15-3475-6700 or via email at [email protected]